Elsevier

Pancreatology

Volume 7, Issue 1, May 2007, Pages 45-52
Pancreatology

Evaluation of Topoisomerase IIa Expression in Pancreatic Ductal Adenocarcinoma: A Pilot Study Using Chromogenic in situ Hybridization and Immunohistochemistry on Tissue Microarrays

https://doi.org/10.1159/000101877Get rights and content

Abstract

Background/Aims: To co-evaluate topoisomerase Ila (Topo Ila) protein expression and gene status in pancreatic ductal adenocarcinoma, determining the potential prognostic impact of its alterations. Methods: Using tissue microarrays, 50 sporadic, primary pancreatic ductal adenocarcinomas were cored twice and re-embedded into one paraffin block with a core diameter of 1 mm. Immunohistochemistry and chromogenic in situ hybridization were performed in serial tissue sections for the detection of protein expression levels, chromosome 17 and Topo Ila gene status, respectively. Finally using a semi-automated image analysis system we evaluated the levels of protein expression. Results: A significant proportion of the tumors showed Topo Ila overexpression (32/50 or 64%). Gene amplification and deletion were detected in 9 and 4 cases, respectively, associated with protein overexpression. Aneuploidy regarding chromosome 17 was observed in 19/50 tumors and correlated with poor survival rate (Cox regression test: p = 0.001). Topo Ila protein expression was strongly correlated with stage (p = 0.021) and grade (p = 0.034). Conclusions: Topo Ila gene amplification correlates with protein overexpression, but not vice versa. This is a crucial observation for the application of targeted chemotherapies, such as anthracyclines, only in subgroups of patients, according to molecular deregulation criteria and not only to immunohistochemical results. Also, chromosome 17 and not Topo Ila gene instability can be used as a potential independent prognostic factor.

References (33)

  • Y Yarden

    Biology of HER2 and its importance in breast cancer

    Oncology

    (2001)
  • JMV Roman et al.

    Comparative assays for the HER2/neu oncogene status in breast cancer

    Arch Pathol Lab Med

    (2004)
  • AD Watters et al.

    Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma

    Breast Cancer Res Treat

    (2003)
  • IM Shin et al.

    Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis

    Cancer Res

    (2001)
  • EH Mahlamaki et al.

    Comparative genomic hybridization reveals frequent gains of 20q, 8q, 11q, 12p, and 17q and losses of 18q, 9p and 15q in pancreatic cancer

    Genes Chromosomes Cancer

    (1997)
  • H Brustmann

    Immunohistochemical detection of human telomerase reverse tran-scriptase (h-TERT), topoisomerase IIa expression and apoptosis in endometrial adenocarcinoma and atypical hyperplasia

    Int J Gynecol Pathol

    (2005)
  • Cited by (17)

    • Identification of a novel catalytic inhibitor of topoisomerase II alpha that engages distinct mechanisms in p53<sup>wt</sup> or p53<sup>−/−</sup> cells to trigger G2/M arrest and senescence

      2022, Cancer Letters
      Citation Excerpt :

      Topo II enzyme is unquestionably one of the most critical proteins required for the untangling of newly replicated chromosomes. Owing to its importance in regulating cell cycle events and the fact that overexpression in human cancers correlates with advanced disease grade/stage and poor overall survival [18–22], topo IIα is an attractive therapeutic target. Logically, there is heightened interest in the identification and development of novel and more selective topo IIα inhibitors with minimal off-target effects.

    • The basics of immunohistochemistry

      2020, In Situ Molecular Pathology and Co-expression Analyses
    • The basics of in situ hybridization

      2020, In Situ Molecular Pathology and Co-expression Analyses
    • The biochemical basis of in situ hybridization and immunohistochemistry

      2020, In Situ Molecular Pathology and Co-expression Analyses
    • Opportunities for translation: Targeting DNA repair pathways in pancreatic cancer

      2014, Biochimica et Biophysica Acta - Reviews on Cancer
      Citation Excerpt :

      In comparison, etoposide is considered a specific topoisomerase II inhibitor, and is used in the treatment of a number of solid malignancies [123]. Two studies reported that the gene encoding topoisomerase II, TOP2A, is amplified in 60–90% of PDAC cases where it is frequently co-amplified with ERBB2 which is found on the same chromosome [133,134]. However, the theranostic value of this is uncertain, and clinical trials involving topoisomerase II poisons have focused on their combination with other cytotoxic agents [124,135–139] but have not been found to be more effective or less toxic compared with other chemotherapeutic treatment approaches for PDAC.

    • Increased topoisomerase IIα expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis

      2009, Cancer Letters
      Citation Excerpt :

      Alterations of HER2 and TOP2A have been reported in gastric cancer, with some evidence suggesting that TOP2A amplification might be the more frequently occurring of the two, although reports are conflicting [4,27]. TOP2A alterations have also been reported in other gastrointestinal cancers, including pancreatic cancer [28]; however, data on TOP2A copy number alterations in CRC are surprisingly limited [9]. The association between topoisomerase IIα expression and both advancing tumor stage and poor differentiation suggest that the protein may play a role in CRC progression.

    View all citing articles on Scopus
    1

    Capt. E. Tsiambas, MD 19B Symis Street, Ag Paraskevi GR-15341 Athens (Greece) Tel./Fax +30 210 729 7977

    View full text